Efficacy of CLAE Chemotherapy Regimen Followed by Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Leukemia.
10.19746/j.cnki.issn.1009-2137.2023.03.010
- Author:
Shan-Dong TAO
1
,
2
;
Li-Xiao SONG
1
,
2
;
Yuan DENG
1
,
2
;
Yue CHEN
1
,
2
;
Xin ZHANG
1
,
2
;
Bang-He DING
1
,
2
;
Chun-Ling WANG
1
,
2
;
Liang YU
1
,
3
Author Information
1. Department of Hematology, The Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China
2. Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.
3. Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China.E-mail: yuliangha@163.com.
- Publication Type:Journal Article
- Keywords:
CLAE regimen;
acute leukemia;
allogeneic hematopoietic stem cell transplantation;
relapsed/refractory
- MeSH:
Male;
Humans;
Busulfan/therapeutic use*;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Treatment Outcome;
Leukemia, Myeloid, Acute/etiology*;
Acute Disease;
Graft vs Host Disease/prevention & control*
- From:
Journal of Experimental Hematology
2023;31(3):677-684
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the efficacy and safety of CLAE intensive chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with relapsed/refractory acute leukemia (R/R AL).
METHODS:CLAE regimen [cladribine 5 mg/(m2·d), d 1-5; cytarabine 1.5 g/(m2·d), d 1-5; etoposide 100 mg/(m2·d), d 3-5] followed by allo-HSCT was used to treat 3 R/R AL patients. The patients received CLAE chemotherapy in relapsed or refractory status and underwent bone marrow puncture to judge myelodysplastic state. After an interval of 3 to 5 days, followed by preconditioning regimen for allo-HSCT [fludarabine 30 mg/(m2·d), d -7 to d -3; busulfan 0.8 mg/kg q6h, d -6 to d -3 or d -5 to d -2. If the bone marrow hyperplasia was not active and the blasts were less than 10%, busulfan should be used for 3 days. If the bone marrow hyperplasia was active and the blasts were more than 10%, busulfan should be used for 4 days]. Cyclosporin A, mycophenolate mofetil and short-term methotrexate were used for graft-versus-host disease (GVHD) prevention. After transplantation, the status of minimal residual disease (MRD) and bone marrow chimerism were regularly monitored in all 3 patients, and demethylation drugs or dasatinib were used to prevent recurrence 3 months after transplantation.
RESULTS:2 patients with t(11;19) translocation and relapse/refractory acute myeloid leukemia recurred within 6 months after induction of remission, and received intensive chemotherapy with CLAE regimen followed by haploidentical allo-HSCT and unrelated donor allo-HSCT, respectively. The two patients both relapsed 6 months after transplantation, then achieved complete remission by donor lymphocyte infusion, interferon, interleukin-2 and other methods, and disease-free survival was 2 years after transplantation. The other patient was chronic myelogenous leukemia who developed acute lymphoblastic leukemia during oral administration of tyrosine kinase inhibitor, accompanied by T315I and E255K mutations in ABL1 kinase region and additional chromosomal abnormalities. After morphological remission by induction chemotherapy, central nervous system leukemia was complicated. Intensive chemotherapy with CLAE regimen followed by sibling allo-HSCT was performed in the positive state of MRD. The patient relapsed 3 months after transplantation, and achieved remission after chimeric antigen receptor T-cell (CAR-T) therapy, however, he died 5 months after transplantation because of severe cytokine release syndrome (CRS) and GVHD.
CONCLUSION:CLAE regimen followed by allo-HSCT may be an effective salvage treatment option for R/R AL patients to prolong the overall survival.
